Shanghai Launches China's First TCM IP Rights Transfer Platform
This article was originally published in PharmAsia News
Executive SummaryShanghai Pudong Intellectual Property Center recently launched China's first IP rights transfer platform for TCM to pave the way for TCM research commercialization. A total of 140 enterprises and institutions, of which 80 are from Shanghai, have joined the initiative. Members can access the platform's website and use patent information search and analysis, project supply-and-demand intelligence, as well as TCM patent market evaluation. Although the platform builds on the foundation of State Intellectual Property Office's patent database, it provides specialized search functions such as identification of keywords with TCM characteristics. However, officers in charge admitted that the current supply and demand is unbalanced due to relatively few TCM innovative achievements. (Click here for more - Chinese language)
You may also be interested in...
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.
Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.